Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(11):859-860; doi:10.1093/jnci/92.11.859
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Davidson, N. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davidson, N. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 11, 859-860, June 7, 2000
© 2000 Oxford University Press

EDITORIALS

Combined Endocrine Therapy for Breast Cancer— New Life for an Old Idea?

Nancy E. Davidson

Correspondence to: Nancy E. Davidson, M.D., The Johns Hopkins Oncology Center, 1650 Orleans St., Rm. 409, Baltimore, MD 21231-1000 (e-mail: davidna@jhmi.edu).

Endocrine therapy has been a mainstay of breast cancer treatment for more than 100 years. The first interventions, oophorectomy for premenopausal women and pharmacologic doses of estrogen for postmenopausal women, have been supplanted by targeted therapy, including selective estrogen receptor modulators (SERMs) like tamoxifen, luteinizing hormone-releasing hormone (LHRH) agonists, and aromatase inhibitors. The initial attempts to combine hormonal therapies generally led to the finding of increased response rates but at the expense of higher toxicity and without an obvious survival advantage when compared with the survival with sequential monotherapy. These results have led to the current practice of serial hormonal manipulation in advanced breast cancer—i.e., the use of one endocrine therapy until disease progression, followed by a second intervention until its failure and so on. In practice, this means that a strategy of tamoxifen followed by ovarian ablation or . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
R. Jakesz, H. Hausmaninger, E. Kubista, M. Gnant, C. Menzel, T. Bauernhofer, M. Seifert, K. Haider, B. Mlineritsch, P. Steindorfer, et al.
Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5
J. Clin. Oncol., December 15, 2002; 20(24): 4621 - 4627.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Yang, D. L. Phillips, A. T. Ferguson, W. G. Nelson, J. G. Herman, and N. E. Davidson
Synergistic Activation of Functional Estrogen Receptor (ER)-{alpha} by DNA Methyltransferase and Histone Deacetylase Inhibition in Human ER-{alpha}-negative Breast Cancer Cells
Cancer Res., October 1, 2001; 61(19): 7025 - 7029.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. G.M. Klijn, R.W. Blamey, F. Boccardo, T. Tominaga, L. Duchateau, and R. Sylvester
Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized Trials
J. Clin. Oncol., January 15, 2001; 19(2): 343 - 353.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. G. M. Klijn and L. Duchateau
RESPONSE: Re: Combined Treatment With Buserelin and Tamoxifen in Premenopausal Metastatic Breast Cancer: a Randomized Study
J Natl Cancer Inst, December 20, 2000; 92(24): 2041 - 2042.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. J. Powles
Re: Combined Treatment With Buserelin and Tamoxifen in Premenopausal Metastatic Breast Cancer: a Randomized Study
J Natl Cancer Inst, December 20, 2000; 92(24): 2040a - 2041a.
[Full Text] [PDF]